CureVac N.V.
| NASDAQ: CVAC | Healthcare / Biotechnology / Greece |
| 6.19 | -0.1100 | -1.75% | Vol 408.36K | 1Y Perf -24.82% |
| Oct 4th, 2023 16:00 DELAYED |
| BID | 6.00 | ASK | 6.47 | ||
| Open | 6.38 | Previous Close | 6.30 | ||
| Pre-Market | - | After-Market | 6.35 | ||
| - - | 0.16 2.58% |
| Target Price | 17.67 | Analyst Rating | Moderate Buy 1.75 | |
| Potential % | 185.46 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★+ 49.04 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★★+ 56.10 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 9.84 | Earnings Rating | — | |
| Market Cap | 1.39B | Earnings Date | 16th Nov 2023 | |
| Alpha | -0.04 | Standard Deviation | 0.31 | |
| Beta | 2.81 |
Today's Price Range 6.176.38 | 52W Range 5.4712.79 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -4.77% | ||
| 1 Month | -30.76% | ||
| 3 Months | -39.49% | ||
| 6 Months | -9.77% | ||
| 1 Year | -24.82% | ||
| 3 Years | -87.74% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -16.90 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -8.50 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -18.40 | |||
Return on invested Capital Q | -7.87 | |||
Return on invested Capital Y | -56.41 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 4.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -14.20 | ||||
| 2.39 | ||||
| 36.09 | ||||
| 9.20 | ||||
| -5.20 | ||||
| -2.35 | ||||
| 2.57 | ||||
| 3.46 | ||||
| 1.04B | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 3.20 | ||||
| 3.60 | ||||
| 0.06 | ||||
| 0.07 | ||||
| -35.80 | ||||
| Leverage Ratio | 1.50 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -79.50 | ||||
| -125.40 | ||||
| -96.80 | ||||
| - | ||||
| -87.02 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 54.63M | ||||
| 0.29 | ||||
| 75.62 | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.28 | -0.33 | -17.86 |
| Q01 2023 | -0.29 | -0.29 | 0.00 |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 16th Nov 2023 |
| Estimated EPS Next Report | -0.26 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 408.36K |
| Shares Outstanding | 223.84K |
| Shares Float | 152.21M |
| Trades Count | 3.30K |
| Dollar Volume | 2.53M |
| Avg. Volume | 874.18K |
| Avg. Weekly Volume | 1.59M |
| Avg. Monthly Volume | 577.42K |
| Avg. Quarterly Volume | 457.43K |
CureVac N.V. (NASDAQ: CVAC) stock closed at 6.19 per share at the end of the most recent trading day (a -1.75% change compared to the prior day closing price) with a volume of 408.36K shares and market capitalization of 1.39B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 484 people. CureVac N.V. CEO is Franz-Werner Haas.
The one-year performance of CureVac N.V. stock is -24.82%, while year-to-date (YTD) performance is 2.65%. CVAC stock has a five-year performance of %. Its 52-week range is between 5.47 and 12.79, which gives CVAC stock a 52-week price range ratio of 9.84%
CureVac N.V. currently has a PE ratio of -14.20, a price-to-book (PB) ratio of 2.39, a price-to-sale (PS) ratio of 36.09, a price to cashflow ratio of 9.20, a PEG ratio of -, a ROA of -8.50%, a ROC of -18.40% and a ROE of -16.90%. The company’s profit margin is -87.02%, its EBITDA margin is -96.80%, and its revenue ttm is $54.63 Million , which makes it $0.29 revenue per share.
Of the last four earnings reports from CureVac N.V., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.26 for the next earnings report. CureVac N.V.’s next earnings report date is 16th Nov 2023.
The consensus rating of Wall Street analysts for CureVac N.V. is Moderate Buy (1.75), with a target price of $17.67, which is +185.46% compared to the current price. The earnings rating for CureVac N.V. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
CureVac N.V. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
CureVac N.V. has a Sell technical analysis rating based on Technical Indicators (ADX : 60.66, ATR14 : 0.46, CCI20 : -138.99, Chaikin Money Flow : -0.22, MACD : -0.63, Money Flow Index : 17.59, ROC : -20.23, RSI : 22.27, STOCH (14,3) : 25.90, STOCH RSI : 0.41, UO : 39.12, Williams %R : -74.10), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of CureVac N.V. in the last 12-months were:
CureVac N.V.
CureVac NV a clinical-stage biopharmaceutical company, developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. The company's product portfolio includes clinical and pre-clinical candidates across multiple disease indications in oncology, prophylactic vaccines and protein therapy. Its clinical programs are CV8102, which it is evaluating in a Phase 1 clinical trial for the treatment of four types of solid tumors, and CV7202, which it is investigating in a Phase 1 clinical trial for potential vaccination against rabies. It is also rapidly advancing its mRNA vaccine program against coronavirus SARS- CoV-2), for which the company initiated a Phase 1 clinical trial.
CEO: Franz-Werner Haas
Telephone: +49 707198830
Address: Friedrich-Miescher-Strasse 15, Tubingen 72076, BW, DE
Number of employees: 484
TipRanks News for CVAC
Fri, 29 Sep 2023 12:40 GMT Analysts Offer Insights on Healthcare Companies: Merus (MRUS), CureVac (CVAC) and Roche Holding AG (OtherRHHVF)
- TipRanks. All rights reserved.
